Lutathera & Pluvicto

Closed Pre-Solicitation Posted

Not the latest version. See the latest special notice from .

Solicitation number
W81K0022Q0097
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
Jbsa Ft Sam Houston, Texas 78234, United States

Notice details come from SAM.gov. Updated .

About this opportunity

This notice seeks information for potential future procurements of Lutathera and Pluvicto doses from the Regional Health Contracting Office on behalf of the San Antonio Military Medical Center. The doses must be FDA approved Lu-177 Dotatate and Lu-177 Vipivotide Tetraxetan indicated for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors and prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer, respectively. Interested parties must provide organizational information and tailored capability statements by May 13, 2022 to be considered for future solicitations under NAICS 325412 for the anticipated period of performance of October 1, 2022 through September 30, 2023.

There is no set-aside designated for this potential procurement. The NAICS is 325412 with a size standard of 1,250 employees. The anticipated contract would be for a 4 dose treatment regimen of Lutathera given every 8 weeks and a treatment regimen of Pluvicto every 6 weeks for up to 6 doses for an unknown number of patients during the one year period of performance. This notice seeks information for planning purposes only and does not guarantee participation in any future solicitation.

Notice text

The Regional Health Contracting Office - Central is issuing this Sources Sought Notice on behalf of San Antonio Military Medical Center (SAMMC), JBSA - Fort Sam Houston, Texas. Any responses to this Sources Sought Notice will be used for planning purposes only. Based on the responses to this notice, the requirement may be set-aside for small businesses, procured through full-and-open competition, or result in a sole-source contract. The proposed North American Industry Classification System (NAICS) Code is 325412 with a corresponding size standard of 1,250 employees. This notice is not a solicitation of offers, nor is it a notice to proceed. SAMMC has a requirement for a LUTATHERA and PLUVICTO doses. This requirement is for two FDA Approved products. Lutathera is for Dotatate, which is indicated for the imaging and treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Pluvicto is for the treatment of adult patients with prostrate specific membrane antigen-positive metastatic castration-resistant prostate cancer. The anticipated period of performance of 1 October 2022 - 30 September 2023.

Salient Characteristics:

Lutetium Lu-177 Dotatate (Lutathera)

Must be FDA approved.

Must be Lu-177 Dotatate

Must be indicated for treatment of somatostatin receptor-positive gastroenterpancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.

Should be a 4 dose treatment regimen given every 8 weeks

Lutetium Lu-177 Vipivotide Tetraxetan (Pluvicto)

Must be FDA approved

Must be Lu-177 Vipivotide Tetraxetan

Must be indicated for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

Should be a treatment regimen of every 6 weeks for up to 6 doses.

If your organization has the potential capacity to provide Lutathera, please provide the following information:

1) Organization name, address, e-mail address, Web site address, telephone number, and size (small versus large business, and any other socio-economic categories) and type of ownership for the organization;

2) Tailored capability statements addressing the particulars of this effort, with appropriate documentation supporting claims of organizational capability, to include proof of authorization to provide supplies and analyzer as well as maintenance and repair services on above-listed equipment. THERE IS NO SOLICITATION AT THIS TIME. This request for capability information does not constitute a request for proposals; submission of any information in response to this notice is purely voluntary; the Government assumes no financial responsibility for any costs incurred.

Contractors responding to this sources sought notice are advised their response does not ensure participation in future solicitations or contract awards.  The Government will not reimburse any company or individual for any expense associated with preparation or participation in this research.  Interested parties should e-mail responses to cathy.l.harris2.civ@mail.mil by the date identified.

Notice history

Notice Type Posted
Lutathera & Pluvicto Latest special notice Special Notice
This notice Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052 See Section 11 of the Cleveland and Kent, Ohio, United States · NAICS 325412 Veterans Integrated Service Network 10 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity